Navidea Biopharmaceuticals Key Executives
This section highlights Navidea Biopharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Navidea Biopharmaceuticals
(Showing 0 of )
Navidea Biopharmaceuticals Earnings
This section highlights Navidea Biopharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
$0.00
Stock Price
$20.02K
Market Cap
11
Employees
Dublin, OH
Location
Financial Statements
Access annual & quarterly financial statements for Navidea Biopharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Revenue | $65.65K | $531.51K | $915.01K | $26.62K | $322.52K |
| Cost of Revenue | $184.95K | $198.83K | $1.05K | $6.67K | $96.64K |
| Gross Profit | $-119.30K | $332.68K | $913.97K | $19.95K | $225.88K |
| Gross Profit Ratio | -181.71% | 62.59% | 99.89% | 74.95% | 70.04% |
| Research and Development Expenses | $5.97M | $5.14M | $4.93M | $5.34M | $4.22M |
| General and Administrative Expenses | $- | $- | $- | $- | $7.70M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $7.96M | $7.45M | $6.69M | $6.28M | $7.70M |
| Other Expenses | $- | $-14.12K | $-21.86K | $-631.21K | $1.15K |
| Operating Expenses | $13.93M | $12.59M | $11.63M | $10.98M | $11.07M |
| Cost and Expenses | $14.12M | $12.59M | $11.63M | $10.99M | $11.17M |
| Interest Income | $- | $6.00K | $11.34K | $25.00K | $- |
| Interest Expense | $1.10M | $6.36K | $- | $25.29K | $30.80K |
| Depreciation and Amortization | $95.82K | $198.83K | $190.58K | $144.51K | $150.38K |
| EBITDA | $-13.88M | $-11.51M | $-10.64M | $-10.82M | $-10.85M |
| EBITDA Ratio | -21134.32% | -2164.89% | -1162.91% | -40641.69% | -3363.29% |
| Operating Income | $-14.05M | $-12.06M | $-10.71M | $-10.96M | $-10.85M |
| Operating Income Ratio | -21402.08% | -2269.07% | -1170.60% | -41184.60% | -3363.29% |
| Total Other Income Expenses Net | $-1.13M | $345.52K | $-10.51K | $17.68K | $-5.32M |
| Income Before Tax | $-15.18M | $-11.71M | $-10.72M | $-10.94M | $-16.17M |
| Income Before Tax Ratio | -23117.58% | -2204.06% | -1171.75% | -41118.20% | -5013.18% |
| Income Tax Expense | $- | $16.04K | $-81.74K | $707 | $2.75K |
| Net Income | $-15.18M | $-11.73M | $-10.64M | $-10.95M | $-16.13M |
| Net Income Ratio | -23117.58% | -2207.08% | -1162.82% | -41120.85% | -5000.12% |
| EPS | $-0.59 | $-0.40 | $-0.45 | $-0.76 | $-1.89 |
| EPS Diluted | $-0.56 | $-0.40 | $-0.45 | $-0.76 | $-1.89 |
| Weighted Average Shares Outstanding | 29.34M | 29.34M | 23.90M | 14.39M | 8.53M |
| Weighted Average Shares Outstanding Diluted | 30.90M | 29.34M | 23.90M | 14.39M | 8.53M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $610 | $7.52K | $6.52K | $- | $50.35K | $96.38K | $261.05K | $123.74K | $219.25K | $6.77K | $8.92K | $15.22K | $2.68K | $4.89K | $15.89K | $97.56K | $35.04K |
| Cost of Revenue | $36.03K | $36.38K | $- | $50.04K | $134.44K | $473 | $53.23K | $51.71K | $48.56K | $- | $- | $- | $82 | $357 | $609 | $108 | $195 | $238 | $6.13K | $22.82K |
| Gross Profit | $-36.03K | $-36.38K | $- | $-49.43K | $-126.92K | $6.05K | $-53.23K | $-1.36K | $47.82K | $261.05K | $123.74K | $219.25K | $6.69K | $8.56K | $14.61K | $2.57K | $4.70K | $15.65K | $91.43K | $12.21K |
| Gross Profit Ratio | - | - | 0.00% | -8102.62% | -1688.69% | 92.74% | - | -2.70% | 49.61% | 100.00% | 100.00% | 100.00% | 98.79% | 96.00% | 96.00% | 95.97% | 96.02% | 98.50% | 93.72% | 34.86% |
| Research and Development Expenses | $829.61K | $1.11M | $1.27M | $1.89M | $1.19M | $1.72M | $1.17M | $1.37M | $1.05M | $1.50M | $1.22M | $1.27M | $1.38M | $1.28M | $999.27K | $1.73M | $1.80M | $1.07M | $740.58K | $854.44K |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.82M | $- | $- | $1.82M | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-657.13K | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.30M | $1.32M | $1.15M | $1.26M | $3.64M | $1.26M | $1.81M | $2.32M | $1.47M | $1.43M | $2.23M | $1.75M | $1.79M | $1.33M | $1.83M | $1.17M | $1.52M | $1.86M | $1.82M | $1.44M |
| Other Expenses | $- | $-144.81K | $- | $- | $8.42K | $6.73K | $-4.30K | $-10.97K | $2.80K | $-5.69K | $-255 | $-21.08K | $-564 | $-336 | $124 | $-1.73K | $-1.52K | $-3.22K | $-1.14K | $-509 |
| Operating Expenses | $2.13M | $2.43M | $2.42M | $3.15M | $4.82M | $2.93M | $2.98M | $3.69M | $2.52M | $2.93M | $3.45M | $3.02M | $2.91M | $2.35M | $2.69M | $2.77M | $3.09M | $2.69M | $2.53M | $2.21M |
| Cost and Expenses | $2.13M | $2.43M | $2.42M | $3.20M | $4.96M | $2.93M | $2.98M | $3.69M | $2.52M | $2.93M | $3.45M | $3.02M | $2.91M | $2.35M | $2.69M | $2.77M | $3.09M | $2.69M | $2.53M | $2.24M |
| Interest Income | $- | $160.72K | $- | $- | $- | $- | $- | $- | $186 | $1.27K | $- | $- | $- | $15.34K | $- | $3.95K | $- | $- | $9.85K | $- |
| Interest Expense | $- | $614.38K | $263.19K | $- | $- | $- | $3.66K | $1.94K | $3.00K | $1.27K | $2.88K | $- | $- | $15.34K | $2.37K | $1.95K | $11.86K | $1.63K | $9.85K | $- |
| Depreciation and Amortization | $27.03K | $36.38K | $27.55K | $26.47K | $24.70K | $52.35K | $53.23K | $51.71K | $48.56K | $19.86K | $17.75K | $18.89K | $15.40K | $19.26K | $16.84K | $36.72K | $34.29K | $36.73K | $36.78K | $37.30K |
| EBITDA | $-2.10M | $-2.40M | $-1.19M | $-3.20M | $-4.95M | $-2.90M | $-2.96M | $-3.64M | $-2.40M | $-2.65M | $-2.92M | $-2.78M | $-2.88M | $-2.32M | $-2.65M | $-2.74M | $-3.05M | $-2.64M | $-2.40M | $-2.16M |
| EBITDA Ratio | - | - | - | -524539.67% | -65870.02% | -44498.08% | - | -7228.19% | -2493.94% | -1015.06% | -2356.53% | -1268.72% | -42569.36% | -26024.33% | -17439.83% | -102066.12% | -62311.52% | -16583.79% | -2456.82% | -6176.67% |
| Operating Income | $-2.13M | $-2.43M | $-2.42M | $-3.20M | $-4.95M | $-2.92M | $-2.98M | $-3.64M | $-2.42M | $-2.67M | $-3.33M | $-2.80M | $-2.90M | $-2.34M | $-2.67M | $-2.77M | $-3.08M | $-2.67M | $-2.43M | $-2.20M |
| Operating Income Ratio | - | - | - | -524298.36% | -65870.02% | -44832.04% | - | -7228.19% | -2512.69% | -1022.66% | -2691.00% | -1277.34% | -42796.77% | -26240.20% | -17550.49% | -103436.19% | -63012.01% | -16814.87% | -2494.52% | -6283.11% |
| Total Other Income Expenses Net | $-124.00K | $1.03M | $946.04K | $-284.41K | $-757.03K | $-76.86K | $-7.96K | $-12.91K | $-14 | $-4.42K | $362.87K | $-22.56K | $-713 | $15.01K | $-2.25K | $219 | $10.33K | $-1.59K | $8.71K | $-1.04M |
| Income Before Tax | $-2.26M | $-1.39M | $-1.48M | $-3.48M | $-5.71M | $-3.00M | $-2.99M | $-3.65M | $-2.42M | $-2.67M | $-2.97M | $-2.82M | $-2.90M | $-2.33M | $-2.67M | $-2.77M | $-3.07M | $-2.67M | $-2.42M | $-3.24M |
| Income Before Tax Ratio | - | - | - | -570922.62% | -75942.32% | -46011.03% | - | -7253.84% | -2512.70% | -1024.36% | -2397.74% | -1287.62% | -42807.29% | -26071.96% | -17565.26% | -103428.02% | -62800.90% | -16824.88% | -2485.59% | -9243.32% |
| Income Tax Expense | $- | $-8.60M | $- | $- | $765.46K | $83.58K | $7.96K | $-1.94K | $16.04K | $-21.12K | $-15.13K | $-1 | $405.56K | $77.78K | $2 | $-1.42K | $-2 | $-168 | $876 | $-62.58K |
| Net Income | $-2.26M | $6.03M | $-1.48M | $-3.48M | $-5.71M | $-3.00M | $-3.00M | $-3.65M | $-2.44M | $-2.67M | $-2.97M | $-2.82M | $-2.90M | $-2.33M | $-2.67M | $-2.77M | $-3.07M | $-2.67M | $-2.43M | $-3.17M |
| Net Income Ratio | - | - | - | -570922.79% | -75942.32% | -46011.01% | - | -7253.84% | -2529.35% | -1024.36% | -2397.74% | -1287.62% | -42807.29% | -26071.95% | -17565.27% | -103427.99% | -62800.86% | -16819.83% | -2489.85% | -9054.91% |
| EPS | $-0.02 | $0.12 | $-0.05 | $-0.11 | $-0.19 | $-0.10 | $-0.10 | $-0.12 | $-0.08 | $-0.09 | $-0.11 | $-0.11 | $-0.11 | $-0.10 | $-0.13 | $-0.15 | $-0.17 | $-0.24 | $-0.24 | $-0.33 |
| EPS Diluted | $-0.02 | $0.12 | $-0.05 | $-0.11 | $-0.19 | $-0.10 | $-0.10 | $-0.12 | $-0.08 | $-0.09 | $-0.11 | $-0.11 | $-0.11 | $-0.10 | $-0.13 | $-0.15 | $-0.17 | $-0.24 | $-0.24 | $-0.33 |
| Weighted Average Shares Outstanding | 99.36M | 48.24M | 32.65M | 32.38M | 30.73M | 30.27M | 30.21M | 30.16M | 30.12M | 29.12M | 28.07M | 26.72M | 25.84M | 22.76M | 20.20M | 18.28M | 18.04M | 11.10M | 10.02M | 9.50M |
| Weighted Average Shares Outstanding Diluted | 99.36M | 48.24M | 32.65M | 32.38M | 30.73M | 30.27M | 30.21M | 30.16M | 30.12M | 29.12M | 28.07M | 26.72M | 25.84M | 22.76M | 20.20M | 18.28M | 18.04M | 11.10M | 10.02M | 9.50M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $2.00M | $4.23M | $2.67M | $1.05M | $3.48M |
| Short Term Investments | $- | $- | $- | $- | $799.27K |
| Cash and Short Term Investments | $2.00M | $4.23M | $2.67M | $1.05M | $4.28M |
| Net Receivables | $630 | $92.99K | $2.99M | $901.34K | $21.15K |
| Inventory | $427.34K | $151.16K | $169.80K | $-901.34K | $1 |
| Other Current Assets | $780.11K | $908.27K | $700.72K | $967.28K | $1.30M |
| Total Current Assets | $3.20M | $5.38M | $6.53M | $2.92M | $4.97M |
| Property Plant Equipment Net | $155.65K | $248.71K | $382.26K | $311.90K | $162.17K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $1.00M | $785.65K | $620.24K | $385.41K | $428.49K |
| Goodwill and Intangible Assets | $1.00M | $785.65K | $620.24K | $385.41K | $428.49K |
| Long Term Investments | $- | $- | $15.28M | $- | $- |
| Tax Assets | $- | $- | $-15.28M | $- | $- |
| Other Non-Current Assets | $11.77K | $227.19K | $227.19K | $537.81K | $1.44M |
| Total Non-Current Assets | $1.17M | $1.26M | $1.23M | $1.24M | $2.03M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $4.37M | $6.64M | $7.76M | $4.15M | $7.01M |
| Account Payables | $2.12M | $1.42M | $1.16M | $1.11M | $424.72K |
| Short Term Debt | $562.59K | $1.00M | $1.34M | $807.06K | $316.07K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $800.00K | $700.00K | $700.00K | $700.00K | $866.93K |
| Other Current Liabilities | $6.46M | $2.83M | $2.22M | $1.90M | $2.64M |
| Total Current Liabilities | $9.94M | $5.30M | $4.72M | $3.82M | $3.38M |
| Long Term Debt | $1.87M | $20.29K | $296.01K | $512.34K | $- |
| Deferred Revenue Non-Current | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K |
| Deferred Tax Liabilities Non-Current | $- | $-20.29K | $-296.01K | $-512.34K | $-468.49K |
| Other Non-Current Liabilities | $- | $- | $- | $- | $532.55K |
| Total Non-Current Liabilities | $2.57M | $720.29K | $996.01K | $1.21M | $1.23M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $12.51M | $6.02M | $5.71M | $5.03M | $4.61M |
| Preferred Stock | $13 | $72 | $132 | $1 | $- |
| Common Stock | $223.68K | $221.28K | $218.15K | $210.23K | $200.39K |
| Retained Earnings | $-388.00M | $-370.79M | $-359.06M | $-347.67M | $-336.72M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $-4.97M | $902 | $-730 |
| Other Total Stockholders Equity | $379.34M | $370.46M | $360.15M | $345.85M | $338.27M |
| Total Stockholders Equity | $-8.44M | $-106.56K | $1.32M | $-1.61M | $1.73M |
| Total Equity | $-8.14M | $624.74K | $2.05M | $-880.99K | $2.40M |
| Total Liabilities and Stockholders Equity | $4.37M | $6.64M | $7.76M | $4.15M | $7.01M |
| Minority Interest | $292.52K | $731.30K | $731.30K | $731.30K | $668.32K |
| Total Liabilities and Total Equity | $4.37M | $6.64M | $7.76M | $4.15M | $7.01M |
| Total Investments | $- | $- | $15.28M | $- | $799.27K |
| Total Debt | $2.44M | $749.43K | $1.34M | $1.07M | $316.07K |
| Net Debt | $439.76K | $-3.48M | $-1.33M | $21.69K | $-3.16M |
Balance Sheet Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $3.86M | $6.14M | $33.80K | $2.00M | $4.60M | $328.01K | $1.22M | $4.23M | $7.18M | $7.11M | $7.51M | $2.67M | $3.72M | $1.62M | $601.36K | $1.05M | $2.84M | $5.26M | $1.47M | $3.48M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $200.19K | $600.23K | $799.27K |
| Cash and Short Term Investments | $3.86M | $6.14M | $33.80K | $2.00M | $4.60M | $328.01K | $1.22M | $4.23M | $7.18M | $7.11M | $7.51M | $2.67M | $3.72M | $1.62M | $601.36K | $1.05M | $2.84M | $5.26M | $2.07M | $4.28M |
| Net Receivables | $30.87K | $44.71K | $31.04K | $630 | $155.19K | $30.07K | $115.84K | $92.99K | $108.32K | $2.40M | $583.73K | $2.99M | $820.21K | $4.04M | $1.70M | $901.34K | $145.82K | $206.86K | $9.87K | $21.15K |
| Inventory | $460.75K | $460.75K | $460.64K | $427.34K | $193.81K | $315.67K | $322.99K | $151.16K | $178.94K | $178.83K | $166.24K | $169.80K | $-820.21K | $- | $-1.70M | $-901.34K | $-145.82K | $-206.86K | $1 | $1 |
| Other Current Assets | $146.59K | $355.21K | $672.06K | $780.11K | $150.12K | $496.99K | $667.44K | $908.27K | $193.49K | $350.24K | $570.75K | $700.72K | $249.89K | $411.83K | $1.15M | $967.28K | $247.00K | $1.00M | $1.70M | $1.30M |
| Total Current Assets | $4.50M | $7.00M | $1.20M | $3.20M | $5.10M | $1.17M | $2.32M | $5.38M | $7.66M | $10.04M | $8.83M | $6.53M | $4.79M | $6.07M | $3.45M | $2.92M | $3.23M | $6.47M | $3.23M | $4.97M |
| Property Plant Equipment Net | $119.38K | $141.96K | $147.73K | $155.65K | $185.50K | $215.21K | $249.80K | $248.71K | $285.03K | $306.12K | $342.80K | $382.26K | $414.58K | $331.05K | $368.01K | $311.90K | $352.67K | $413.51K | $473.38K | $162.17K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $1.06M | $1.06M | $1.01M | $1.00M | $941.25K | $890.56K | $801.74K | $785.65K | $790.36K | $704.58K | $679.04K | $620.24K | $561.11K | $482.42K | $435.27K | $385.41K | $406.24K | $413.66K | $421.08K | $428.49K |
| Goodwill and Intangible Assets | $1.06M | $1.06M | $1.01M | $1.00M | $941.25K | $890.56K | $801.74K | $785.65K | $790.36K | $704.58K | $679.04K | $620.24K | $561.11K | $482.42K | $435.27K | $385.41K | $406.24K | $413.66K | $421.08K | $428.49K |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $11.77K | $11.77K | $11.77K | $11.77K | $31.77K | $227.19K | $227.19K | $227.19K | $227.19K | $227.19K | $227.19K | $227.19K | $227.19K | $227.19K | $227.19K | $537.81K | $828.43K | $828.43K | $834.98K | $1.44M |
| Total Non-Current Assets | $1.20M | $1.22M | $1.17M | $1.17M | $1.16M | $1.33M | $1.28M | $1.26M | $1.30M | $1.24M | $1.25M | $1.23M | $1.20M | $1.04M | $1.03M | $1.24M | $1.59M | $1.66M | $1.73M | $2.03M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $5.70M | $8.22M | $2.37M | $4.37M | $6.26M | $2.50M | $3.60M | $6.64M | $8.96M | $11.28M | $10.08M | $7.76M | $6.00M | $7.11M | $4.48M | $4.15M | $4.82M | $8.13M | $4.96M | $7.01M |
| Account Payables | $2.07M | $2.01M | $3.17M | $2.12M | $1.74M | $2.43M | $1.56M | $1.42M | $1.21M | $1.08M | $1.23M | $1.16M | $1.12M | $1.16M | $1.45M | $1.11M | $838.97K | $673.02K | $852.61K | $424.72K |
| Short Term Debt | $1.26M | $1.36M | $353.45K | $562.59K | $54.69K | $236.82K | $510.25K | $1.00M | $702.97K | $627.70K | $799.07K | $1.34M | $937.83K | $964.98K | $711.96K | $807.06K | $499.23K | $581.92K | $682.77K | $316.07K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $800.00K | $800.00K | $800.00K | $800.00K | $800.00K | $-118.41K | $800.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $495.00K | $700.00K | $866.93K |
| Other Current Liabilities | $3.85M | $4.14M | $4.93M | $6.46M | $5.84M | $2.66M | $3.10M | $2.83M | $2.18M | $2.32M | $2.13M | $2.22M | $1.96M | $2.02M | $2.19M | $1.90M | $2.24M | $1.82M | $1.88M | $2.64M |
| Total Current Liabilities | $7.98M | $8.31M | $9.25M | $9.94M | $8.43M | $5.32M | $4.90M | $5.30M | $4.10M | $4.02M | $4.16M | $4.72M | $4.01M | $4.15M | $4.35M | $3.82M | $3.58M | $3.82M | $3.42M | $3.38M |
| Long Term Debt | $269 | $534 | $1.96M | $1.87M | $1.79M | $722.37K | $11.30K | $20.29K | $29.04K | $120.47K | $209.44K | $296.01K | $380.24K | $434.32K | $513.70K | $512.34K | $575.06K | $613.75K | $685.99K | $- |
| Deferred Revenue Non-Current | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $800.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K |
| Deferred Tax Liabilities Non-Current | $- | $-700.00K | $- | $- | $-700.00K | $-700.00K | $-11.30K | $-20.29K | $-29.04K | $-120.47K | $-209.44K | $-296.01K | $-380.24K | $- | $-513.70K | $-512.34K | $-575.06K | $-613.75K | $- | $-468.49K |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $3.45M | $- | $- | $63.00K | $63.00K | $63.00K | $532.55K |
| Total Non-Current Liabilities | $700.27K | $700.53K | $2.66M | $2.57M | $2.49M | $1.42M | $811.30K | $720.29K | $729.04K | $820.47K | $909.44K | $996.01K | $1.08M | $4.58M | $1.21M | $1.21M | $1.34M | $1.38M | $1.45M | $1.23M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $8.68M | $9.01M | $11.92M | $12.51M | $10.93M | $6.74M | $5.71M | $6.02M | $4.83M | $4.85M | $5.07M | $5.71M | $5.09M | $8.73M | $5.57M | $5.03M | $4.91M | $5.20M | $4.87M | $4.61M |
| Preferred Stock | $16 | $101 | $13 | $13 | $13 | $27 | $72 | $72 | $72 | $50 | $101 | $132 | $- | $3.45M | $- | $1 | $- | $- | $- | $- |
| Common Stock | $291.08K | $287.15K | $223.85K | $223.68K | $223.15K | $221.36K | $221.35K | $221.28K | $221.16K | $221.14K | $219.70K | $218.15K | $217.37K | $215.54K | $212.19K | $210.23K | $209.06K | $209.06K | $201.05K | $200.39K |
| Retained Earnings | $-385.91M | $-383.65M | $-389.48M | $-388.00M | $-384.52M | $-376.77M | $-373.77M | $-370.79M | $-367.14M | $-364.70M | $-362.02M | $-359.06M | $-356.05M | $-352.75M | $-350.34M | $-347.67M | $-344.90M | $-341.83M | $-339.15M | $-336.72M |
| Accumulated Other Comprehensive Income Loss | $-3.27M | $-1.08M | $-0 | $0 | $- | $- | $- | $- | $- | $- | $-960.86K | $-4.97M | $-882.41K | $-1.34M | $-1.30M | $902 | $- | $188 | $228 | $-730 |
| Other Total Stockholders Equity | $388.89M | $383.37M | $379.41M | $379.34M | $379.34M | $372.02M | $371.15M | $370.46M | $370.32M | $370.18M | $366.08M | $360.15M | $361.00M | $348.07M | $349.61M | $345.85M | $343.93M | $343.88M | $338.38M | $338.27M |
| Total Stockholders Equity | $-3.27M | $-1.08M | $-9.84M | $-8.44M | $-4.96M | $-4.53M | $-2.40M | $-106.56K | $3.40M | $5.70M | $4.28M | $1.32M | $169.88K | $-2.35M | $-1.82M | $-1.61M | $-761.05K | $2.26M | $-573.67K | $1.73M |
| Total Equity | $-2.98M | $-786.58K | $-9.55M | $-8.14M | $-4.67M | $-4.24M | $-2.11M | $624.74K | $4.13M | $6.44M | $5.01M | $2.05M | $901.18K | $-1.62M | $-1.09M | $-880.99K | $-92.74K | $2.93M | $94.64K | $2.40M |
| Total Liabilities and Stockholders Equity | $5.70M | $8.22M | $2.37M | $4.37M | $6.26M | $2.50M | $3.60M | $6.64M | $8.96M | $11.28M | $10.08M | $7.76M | $6.00M | $7.11M | $4.48M | $4.15M | $4.82M | $8.13M | $4.96M | $7.01M |
| Minority Interest | $292.52K | $292.52K | $292.52K | $292.52K | $292.52K | $292.52K | $292.52K | $731.30K | $731.30K | $731.30K | $731.30K | $731.30K | $731.30K | $731.30K | $731.30K | $731.30K | $668.30K | $668.31K | $668.31K | $668.32K |
| Total Liabilities and Total Equity | $5.70M | $8.22M | $2.37M | $4.37M | $6.26M | $2.50M | $3.60M | $6.64M | $8.96M | $11.28M | $10.08M | $7.76M | $6.00M | $7.11M | $4.48M | $4.15M | $4.82M | $8.13M | $4.96M | $7.01M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $200.19K | $600.23K | $799.27K |
| Total Debt | $1.26M | $1.34M | $2.32M | $2.44M | $1.82M | $840.78K | $323.41K | $749.43K | $380.52K | $434.32K | $704.25K | $1.34M | $1.03M | $1.12M | $957.64K | $1.07M | $824.68K | $944.72K | $1.13M | $316.07K |
| Net Debt | $-2.61M | $-4.81M | $2.28M | $439.76K | $-2.78M | $512.76K | $-893.70K | $-3.48M | $-6.80M | $-6.68M | $-6.80M | $-1.33M | $-2.69M | $-495.06K | $356.29K | $21.69K | $-2.02M | $-4.32M | $-343.67K | $-3.16M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|
| Net Income | $-15.18M | $-11.73M | $-10.72M | $-10.95M | $-16.11M |
| Depreciation and Amortization | $95.82K | $76.95K | $70.39K | $144.51K | $150.38K |
| Deferred Income Tax | $- | $-267.27K | $5.65K | $60.10K | $5.29M |
| Stock Based Compensation | $301.35K | $471.26K | $230.52K | $232.06K | $306.70K |
| Change in Working Capital | $5.12M | $947.17K | $1.84M | $1.12M | $13.83M |
| Accounts Receivables | $92.36K | $655.32K | $1.95M | $-68.24K | $12.93M |
| Inventory | $-459.19K | $18.64K | $-169.80K | $68.24K | $1.35M |
| Accounts Payables | $701.22K | $259.60K | $49.65K | $687.35K | $-430.32K |
| Other Working Capital | $4.78M | $13.61K | $13.61K | $435.07K | $-15.04K |
| Other Non Cash Items | $675.47K | $284.66K | $401.74K | $34.39K | $806.27K |
| Net Cash Provided by Operating Activities | $-8.99M | $-10.22M | $-8.17M | $-9.35M | $4.28M |
| Investments in Property Plant and Equipment | $-63.09K | $-329.42K | $-413.87K | $-56.70K | $-46.19K |
| Acquisitions Net | $- | $- | $1.04K | $27.12K | $46.19K |
| Purchases of Investments | $- | $- | $- | $- | $-600.00K |
| Sales Maturities of Investments | $- | $- | $- | $800.00K | $1.60M |
| Other Investing Activities | $-327.26K | $-304.21K | $1.04K | $27.12K | $-46.19K |
| Net Cash Used for Investing Activities | $-390.35K | $-329.42K | $-412.83K | $770.42K | $953.81K |
| Debt Repayment | $1.98M | $-491.77K | $-2.55K | $-359.06K | $-395.57K |
| Common Stock Issued | $30 | $4.35K | $4.44M | $7.09M | $3.00M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $5.16M | $12.60M | $5.77M | $-572.27K | $-7.15M |
| Net Cash Used Provided by Financing Activities | $7.14M | $12.11M | $10.21M | $6.16M | $-4.55M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-2.24M | $1.56M | $1.62M | $-2.43M | $680.88K |
| Cash at End of Period | $2.00M | $4.23M | $2.67M | $1.05M | $3.48M |
| Cash at Beginning of Period | $4.23M | $2.67M | $1.05M | $3.48M | $2.80M |
| Operating Cash Flow | $-8.99M | $-10.22M | $-8.17M | $-9.35M | $4.28M |
| Capital Expenditure | $-390.35K | $-329.42K | $-413.87K | $-56.70K | $-46.19K |
| Free Cash Flow | $-9.38M | $-10.55M | $-8.59M | $-9.41M | $4.23M |
Cash Flow Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 | December 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-9.68M | $6.03M | $-1.48M | $-3.48M | $-5.71M | $-3.00M | $-2.99M | $-3.65M | $-2.44M | $-2.67M | $-2.97M | $-2.82M | $-2.90M | $-2.33M | $-2.67M | $-2.77M | $-3.07M | $-2.67M | $-2.43M | $-3.16M |
| Depreciation and Amortization | $27.03K | $27.13K | $27.55K | $26.47K | $24.70K | $21.77K | $22.88K | $21.28K | $18.07K | $19.86K | $17.75K | $18.89K | $15.40K | $19.26K | $16.84K | $36.72K | $34.29K | $36.73K | $36.78K | $37.30K |
| Deferred Income Tax | $- | $185.06K | $- | $- | $- | $- | $- | $78.77K | $19.96K | $- | $-366.00K | $6.70K | $-1.04K | $- | $- | $58.43K | $- | $- | $- | $1.03M |
| Stock Based Compensation | $10 | $-33.84K | $72 | $42 | $41.05K | $40.55K | $184.85K | $99.62K | $108.16K | $142.18K | $121.30K | $94.17K | $62.52K | $34.59K | $39.25K | $53.88K | $50.04K | $66.16K | $61.98K | $45.46K |
| Change in Working Capital | $-35.06K | $-1.64M | $779.46K | $834.35K | $3.52M | $690.00K | $77.07K | $635.20K | $221.27K | $66.61K | $24.09K | $26.32K | $125.95K | $90.44K | $1.60M | $-125.35K | $645.26K | $437.55K | $164.97K | $-400.39K |
| Accounts Receivables | $13.84K | $-13.67K | $-30.41K | $154.56K | $-125.12K | $85.78K | $-22.85K | $-30.68K | $150.50K | $-108.80K | $-21.41K | $127.30K | $24.51K | $-104.30K | $860.92K | $-68.24K | $61.05K | $-197.00K | $11.28K | $65.78K |
| Inventory | $- | $-110 | $-33.29K | $-283.54K | $-11.14K | $7.32K | $-171.84K | $27.78K | $-105 | $-12.59K | $3.56K | $-169.80K | $- | $- | $- | $-343.82K | $- | $- | $-286.15K | $-270.36K |
| Accounts Payables | $62.85K | $-1.16M | $1.05M | $384.02K | $-688.13K | $861.72K | $143.62K | $215.09K | $126.16K | $-154.05K | $72.40K | $45.85K | $-45.04K | $-293.37K | $342.21K | $273.10K | $165.95K | $-179.59K | $427.89K | $-190.81K |
| Other Working Capital | $-111.75K | $-458.29K | $-205.43K | $579.31K | $744.72K | $-77.03K | $128.15K | $423.01K | $-55.28K | $233.25K | $-30.46K | $22.96K | $170.99K | $383.81K | $393.75K | $13.61K | $479.31K | $617.14K | $11.94K | $-5.00K |
| Other Non Cash Items | $6.86M | $115.70K | $-1.05M | $188.64K | $114.78K | $107.82K | $146.34K | $88.86K | $58.00K | $30.58K | $107.22K | $120.19K | $65.40K | $146.84K | $69.31K | $14.80K | $1.67K | $19.59K | $427.88K | $324.49K |
| Net Cash Provided by Operating Activities | $-2.82M | $4.69M | $-1.72M | $-2.43M | $-1.86M | $-2.14M | $-2.56M | $-2.73M | $-2.01M | $-2.41M | $-3.06M | $-2.56M | $-2.63M | $-2.03M | $-951.32K | $-2.73M | $-2.34M | $-2.11M | $-2.17M | $-2.13M |
| Investments in Property Plant and Equipment | $-16.52K | $-65.34K | $-15.07K | $-72.04K | $-78.93K | $-121.19K | $-118.19K | $-89.44K | $-133.21K | $-39.30K | $-67.47K | $-82.58K | $-207.62K | $-59.23K | $-64.44K | $- | $- | $- | $- | $-26.88K |
| Acquisitions Net | $- | $336 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $43.03K |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-400.00K |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $200.00K | $400.00K | $200.00K | $400.00K |
| Other Investing Activities | $24.68K | $336 | $-24.34K | $- | $-64.50K | $-114.55K | $-76.17K | $-84.97K | $-115.17K | $-36.59K | $-67.47K | $-75.91K | $1.04K | $1 | $-1 | $-57.96K | $1.51K | $400.00K | $26.88K | $-43.03K |
| Net Cash Used for Investing Activities | $8.16K | $-65.00K | $-39.41K | $-72.04K | $-78.93K | $-121.19K | $-118.19K | $-89.44K | $-133.21K | $-39.30K | $-67.47K | $-82.58K | $-206.57K | $-59.23K | $-64.44K | $-57.96K | $201.51K | $400.00K | $226.88K | $-26.88K |
| Debt Repayment | $-138.57K | $-204.50K | $-200.54K | $-64.66K | $1.00M | $1.39M | $-339.45K | $-112.33K | $- | $-190.55K | $-188.89K | $-62.60K | $-44.25K | $234.34K | $-130.04K | $-42.99K | $-80.02K | $-118.77K | $-117.28K | $-77.36K |
| Common Stock Issued | $-50.00K | $1.69M | $- | $30 | $- | $- | $- | $2.21K | $2 | $2.12K | $13 | $25.00K | $1.39M | $2.18M | $850.00K | $1.04M | $- | $6.00M | $50.30K | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-50.00K | $1.69M | $- | $-35.13K | $5.21M | $-14.63K | $- | $-17.36K | $4.42M | $2.25M | $8.16M | $1.62M | $3.60M | $700.00K | $-150.00K | $- | $- | $-572.27K | $- | $- |
| Net Cash Used Provided by Financing Activities | $-188.57K | $1.48M | $-200.54K | $-99.76K | $6.21M | $1.37M | $-339.45K | $-127.48K | $2.21M | $2.06M | $7.97M | $1.59M | $4.94M | $3.11M | $569.96K | $997.01K | $-80.02K | $5.31M | $-66.98K | $-77.36K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-2.28M | $6.11M | $-1.96M | $-2.60M | $4.27M | $-889.10K | $-3.01M | $-2.95M | $62.11K | $-393.22K | $4.84M | $-1.05M | $2.11M | $1.02M | $-445.80K | $-1.79M | $-2.22M | $3.59M | $-2.01M | $-2.23M |
| Cash at End of Period | $3.86M | $6.14M | $33.80K | $2.00M | $4.60M | $328.01K | $1.22M | $4.23M | $7.18M | $7.11M | $7.51M | $2.67M | $3.72M | $1.62M | $601.36K | $1.05M | $2.84M | $5.06M | $1.47M | $3.48M |
| Cash at Beginning of Period | $6.14M | $33.80K | $2.00M | $4.60M | $328.01K | $1.22M | $4.23M | $7.18M | $7.11M | $7.51M | $2.67M | $3.72M | $1.62M | $601.36K | $1.05M | $2.84M | $5.06M | $1.47M | $3.48M | $5.71M |
| Operating Cash Flow | $-10.25M | $4.69M | $-1.72M | $-2.43M | $-1.86M | $-2.14M | $-2.56M | $-2.73M | $-2.01M | $-2.41M | $-3.06M | $-2.56M | $-2.63M | $-2.03M | $-951.32K | $-2.73M | $-2.34M | $-2.11M | $-2.17M | $-2.13M |
| Capital Expenditure | $-16.52K | $-65.34K | $-39.41K | $-72.04K | $-78.93K | $-121.19K | $-118.19K | $-89.44K | $-133.21K | $-39.30K | $-67.47K | $-82.58K | $-207.62K | $-59.23K | $-64.44K | $- | $- | $- | $- | $-26.88K |
| Free Cash Flow | $-10.27M | $4.63M | $-1.76M | $-2.51M | $-1.94M | $-2.26M | $-2.67M | $-2.82M | $-2.15M | $-2.45M | $-3.13M | $-2.64M | $-2.84M | $-2.09M | $-1.02M | $-2.73M | $-2.34M | $-2.11M | $-2.17M | $-2.15M |
Navidea Biopharmaceuticals Dividends
Explore Navidea Biopharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Navidea Biopharmaceuticals News
Read the latest news about Navidea Biopharmaceuticals, including recent articles, headlines, and updates.
Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets
COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (“Navidea” or the “Company”) today announced that its Board of Directors has elected to extend the Company's Section 382 Rights Agreement (the “Section 382 Rights Plan”). Originally adopted on April 7, 2022, and set to expire on April 6, 2025, the plan has now been extended to April 7, 2027. The Section 382 Rights Plan is designed to safeguard Navidea's ability to utilize its net operating loss carryforwards (“NOLs”) and other ta.
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the Company's pivotal NAV3-33 clinical trial titled “Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (R.
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
COLUMBUS, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024. The purpose of the special meeting is to consider and vote upon (i) an amendment to the Company's certificate of incorporation to allow stockholders to act by written consent, and (ii.
NYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc. (NAVB)
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to suspend trading in the common stock of Navidea Biopharmaceuticals, Inc. (the “Company”) — ticker symbol NAVB — from the NYSE American. The staff suspended trading in the Company's common stock because the Listings Qualifications Panel (the “Panel”) of the Committee for Review of the Board of Directors of the Exchange (the “Committee”) had issued a.
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination.
NYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea Biopharmaceuticals, Inc. (the “Company”) — ticker symbol NAVB —from the Exchange. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the “Company Guide”) as the Company was unable to demonstrate t.
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced Dana J Moss, JD has joined the Company's Board of Directors, adding depth in legal advice, strategic business, life sciences and technology in line with Navidea's stated objectives and its Fix, Fund, Propel approach to advancing innovative technology to market. Separat.
Navidea Biopharmaceuticals rejects ProPhase Labs offer
Navidea Biopharmaceuticals Inc. NAVB, -2.38% announced Friday that it had rejected an unsolicited ProPhase Labs Inc. PRPH, +0.08% offer for certain Navidea assets, saying the proposal undervalues Navidea and is not in the best interest of shareholders. ProPhase, a biotech, genomics and diagnostics company, said in a release Thursday that on June 8 it had offered $7 million in cash or $9.1 million in common stock for the assets, with the cash offer equivalent to over two times the then-current market cap of Navidea.
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series K Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on June 27, 2.
Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it received a Notice (the “Notice”) on June 1, 2023 from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide (“Company.
Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the introduction of a Fix, Fund, Propel approach to driving the Company's strategy forward; The Company will issue a press release detailing financial highlights and corporate developments in lieu of hosting conference call and webcast for the first quarter ended March.
Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announces the execution of a letter of intent to sale the Cardinal Milestone Payment for $8 million and execution of a new $2.75 million Equity Line of Credit, led by a longtime Navidea investor, to provide substantial funding for the Company's Phase IIb (NAV3-32) and Phase III.
Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it has signed an Asset Purchase Agreement allowing Meilleur Technologies, Inc.
Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announces the Company has hired G2G Ventures (G2G) as Executive Consultants to provide executive team support for Navidea's aggressive growth plans. Separately, Michael Rosol, Ph.D., has stepped down as Chief Medical Officer for the Company.
Navidea Biopharmaceuticals, Inc. (NAVB) Q4 2022 Earnings Call Transcript
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB ) Q4 2022 Earnings Conference Call March 22, 2023 5:00 PM ET Company Participants Michael Rosol - SVP & Chief Medical Officer Erika Eves - VP, Finance & Administration and Principal Financial & Accounting Officer Joseph Meyer - Controller Alexander Cappello - Independent Chairman Conference Call Participants Edward English - Private Investor Operator Greetings, and welcome to the Navidea Biopharmaceuticals Fourth Quarter Earnings Call and Business Update. [Operator Instructions].
Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the three-month and twelve-month periods ended December 31, 2022.
Navidea Biopharmaceuticals Announces the Notice of Allowance for U.S. Patent Application for Key Component of the Company's Cancer Immunotherapy Pipeline
DUBLIN, Ohio--( BUSINESS WIRE )--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled, “Compositions And Methods For Altering Macrophage Phenotype (US Application #16/832,620).” Broadly, this patent covers the ability of Navidea's constructs to stimulate the body's immune response against tumors through targeted delivery of payloads (e.g., doxorubicin, paclitaxel, and bisphosphonates) that change the nature of macrophages to make them more proinflammatory. These constructs have demonstrated the ability to rally an immune response against tumors and make other therapies work more effectively against those tumors in preclinical studies. If confirmed in clinical trials, the ability to increase the efficacy of cancer therapeutics by harnessing the body's immune system could bring significant benefits to patients.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for NAVB.